HTF Market Intelligence released a new research report of 148 pages on title ‘Irritable Bowel Syndrome – Pipeline Review, H1 2017’ with detailed analysis, forecast and strategies. The study covers key regions and important players such as Cosmo Pharmaceuticals NV, Dong-A ST Co., Ltd., Eisai Co Ltd etc.
Request a sample report @ https://www.htfmarketreport.com/sample-report/437120-irritable-bowel-syndrome-pipeline-review
Irritable Bowel Syndrome – Pipeline Review, H1 2017
The latest Pharmaceutical and Healthcare disease pipeline guide Irritable Bowel Syndrome – Pipeline Review, H1 2017, provides an overview of the Irritable Bowel Syndrome (Gastrointestinal) pipeline landscape.
Inflammatory Bowel Diseases (IBD) is a broad term that describes conditions with chronic or recurring immune response and inflammation of the gastrointestinal tract. Signs and symptoms include abdominal cramps and pain, diarrhea that may be bloody, weight loss, loss of appetite and fever. The predisposing factors include age, family history, smoking and some pain killers. Treatment includes corticosteroids, immune suppressors, antibiotics and pain relievers.
The Pharmaceutical and Healthcare latest pipeline guide Irritable Bowel Syndrome – Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Irritable Bowel Syndrome (Gastrointestinal), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Irritable Bowel Syndrome (Gastrointestinal) pipeline guide also reviews of key players involved in therapeutic development for Irritable Bowel Syndrome and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical and Discovery stages are 2, 3, 12, 7, 11 and 2 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 1 molecules, respectively.
Irritable Bowel Syndrome (Gastrointestinal) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from The proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Buy this report @ https://www.htfmarketreport.com/buy-now?format=1&report=437120
– The pipeline guide provides a snapshot of the global therapeutic landscape of Irritable Bowel Syndrome (Gastrointestinal).
– The pipeline guide reviews pipeline therapeutics for Irritable Bowel Syndrome (Gastrointestinal) by companies and universities/research institutes based on information derived from company and industry-specific sources.
– The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
– The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
– The pipeline guide reviews key companies involved in Irritable Bowel Syndrome (Gastrointestinal) therapeutics and enlists all their major and minor projects.
– The pipeline guide evaluates Irritable Bowel Syndrome (Gastrointestinal) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
– The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
– The pipeline guide reviews latest news related to pipeline therapeutics for Irritable Bowel Syndrome (Gastrointestinal)
Reasons to buy
– Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
– Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
– Find and recognize significant and varied types of therapeutics under development for Irritable Bowel Syndrome (Gastrointestinal).
– Classify potential new clients or partners in the target demographic.
– Develop tactical initiatives by understanding the focus areas of leading companies.
– Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
– Formulate corrective measures for pipeline projects by understanding Irritable Bowel Syndrome (Gastrointestinal) pipeline depth and focus of Indication therapeutics.
– Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
– Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Companies Mentioned in the Report
4D Pharma PLC
A. Menarini Industrie Farmaceutiche Riunite Srl
Alfa Wassermann SpA
Astellas Pharma Inc
CJ HealthCare Corp
ConSynance Therapeutics Inc
Cosmo Pharmaceuticals NV
Dong-A ST Co., Ltd.
Eisai Co Ltd
Enterome Bioscience SA
Innovative Med Concepts LLC
Ironwood Pharmaceuticals Inc
Kissei Pharmaceutical Co Ltd
Lexicon Pharmaceuticals Inc
Napo Pharmaceuticals Inc
RaQualia Pharma Inc
RedHill Biopharma Ltd
SK Biopharmaceuticals Co Ltd
Sumitomo Dainippon Pharma Co Ltd
Synergy Pharmaceuticals Inc
Synthetic Biologics Inc
Vitality Biopharma Inc
Make an enquiry before buying this Report @ https://www.htfmarketreport.com/enquiry-before-buy/437120-irritable-bowel-syndrome-pipeline-review
Table of Contents
List of Tables 5
List of Figures 6
Global Markets Direct Report Coverage 7
Irritable Bowel Syndrome – Overview 8
Irritable Bowel Syndrome – Therapeutics Development 9
Pipeline Overview 9
Pipeline by Companies 10
Pipeline by Universities/Institutes 13
Products under Development by Companies 14
Products under Development by Universities/Institutes 16
Irritable Bowel Syndrome – Therapeutics Assessment 17
Assessment by Target 17
Assessment by Mechanism of Action 20
Assessment by Route of Administration 23
Assessment by Molecule Type 25
Irritable Bowel Syndrome – Companies Involved in Therapeutics Development 27
4D Pharma PLC 27
A. Menarini Industrie Farmaceutiche Riunite Srl 27
Alfa Wassermann SpA 28
Allergan Plc 28
Ardelyx Inc 29
Astellas Pharma Inc 29
CJ HealthCare Corp 30
ConSynance Therapeutics Inc 30
Cosmo Pharmaceuticals NV 31
Dong-A ST Co., Ltd. 31
Eisai Co Ltd 32
Enterome Bioscience SA 32
GlaxoSmithKline Plc 33
Innovative Med Concepts LLC 33
Ironwood Pharmaceuticals Inc 34
Kissei Pharmaceutical Co Ltd 35
Lexicon Pharmaceuticals Inc 35
Napo Pharmaceuticals Inc 36
Pfizer Inc 36
RaQualia Pharma Inc 37
RedHill Biopharma Ltd 37
SK Biopharmaceuticals Co Ltd 38
Sumitomo Dainippon Pharma Co Ltd 38
View Detailed Table of Content @ https://www.htfmarketreport.com/reports/437120-irritable-bowel-syndrome-pipeline-review
CRAIG FRANCIS (PR & Marketing Manager)
Ph: +1 (206) 317 1218